Abstract

Background and aims: Our first objective was to evaluate the immune response to the adjuvanted 2009 A/H1N1 pandemic (pH1N1) vaccine in inflammatory bowel disease (IBD) patients treated with anti-TNF-α alone or combined with immunosuppressants (IS). Second and third aims were the safety of pH1N1 vaccine and the effects on IBD clinical activity.

Methods: 36 patients with Crohn's disease (CD) and 26 with ulcerative colitis (UC) and thirty-one healthy control (HC) subjects were enrolled. 47 patients were on anti TNF-α maintenance monotherapy and 15 on anti TNF-α combined with IS. Sera were collected at baseline (T0) and 4 weeks after the vaccination (T1) for antibody determination by hemagglutination inhibition (HAI). Disease activity was monitored at T0 and T1.

Results: Seroprotective titers (≥ 1:40) in patients were comparable to HC. Seroconvertion rate (≥ 4 fold increase in HAI titer) was lower than HC in IBD patients (p = 0.009), either on anti TNF-α monotherapy (p = 0.034) or combined with IS (p = 0.011). Geometric mean titer (GMT) of antibodies at T1 was significantly lower in patients on combined therapy versus those on monotherapy (p = 0.0017) and versus HC (p = 0.011). The factor increase of GMT at T1 versus T0 was significantly lower in IBD patients versus HC (p = 0.042), and in those on combined immunosuppression, both versus monotherapy (p = 0.0048) and HC (p = 0.0015). None of the patients experienced a disease flare.

Conclusion: Our study has shown a suboptimal response to pH1N1 vaccine in IBD patients on therapy with anti TNF-α and IS compared to those on anti-TNF-α monotherapy and HC.

Introduction

Patients with Crohn's disease (CD) and ulcerative colitis (UC) have subtle alterations in immunity. Genetic mutations associated with changes in innate immunity (including NOD2 and IL23R) have been found in inflammatory bowel disease (IBD) patients.14 IBD patients are often placed on long term anti-inflammatory and immunosuppressive therapies, including aminosalicylates, corticosteroids, 6-mercaptopurine, azathioprine, methotrexate, and tumor necrosis factor (TNF)-α inhibitors. Although a majority of IBD patients do not develop serious infections, reports of life-threatening infections (e.g. varicella, tubercolosis) have been published, primarily in patients receiving immunosuppressive therapy.58

In April 2009, the US Centers for Disease Control and Prevention (CDC) identified the first two cases of a novel swine origin (H1N1) virus. The lack of immunity to this virus and ease of its human–human transmission resulted in widespread outbreaks in different countries, prompting the World Health Organization to declare an ongoing world pandemic of novel influenza H1N1 on June 11, 2009.9 The clinical manifestations of 2009 H1N1 influenza were similar to seasonal influenza.10 The risk factors for severe infection due to H1N1 influenza were also similar to seasonal influenza and include different chronic underlying medical conditions such as heart, lung, renal and liver disease, cancer, immunosuppression, as well as pregnancy.11,12 The most effective way to prevent influenza and its complications is vaccination. Vaccination against influenza with inactivated vaccines is recommended for inflammatory bowel disease (IBD) patients according to published guidelines both in the US13 and Europe.14 In 2009 the outbreak of pandemic swine influenza of a new H1N1 strain lead to a strong recommendation for vaccination of at risk categories which comprise chronic inflammatory diseases and immunosuppressed patients.15 However, vaccine studies in patients with chronic illnesses suggest that there are varying degrees of serologic response to vaccination. Few studies about the influenza vaccine were conducted in IBD patients and they have shown some conflicting results. In particular, two studies were conducted in pediatric IBD populations. One study16 demonstrated that children with IBD and particularly those receiving both infliximab and immunomodulators had a lower response to some influenza strains in the vaccine compared to HC. At variance, Lu et al.17 in a study on 146 children and young adults with IBD found that influenza vaccination produced a high prevalence of seroprotection in these subjects, particularly against A strains. No differences were detected among non-immunosuppressed and immunosuppressed patients. A few studies conducted in adult IBD patients found that the immune response to vaccinations in IBD patients may depend on the type of immunosuppressive therapy they receive, in particular anti TNF-α therapy.1820 Two of these studies18,19 evaluated the response to H1N1 vaccination in IBD patients.

In recent years the issue of a higher efficacy of a combination of immunosuppressors and anti TNF-α, both in CD21 and in UC22 has been greatly debated; furthermore the potential higher efficacy needs to be balanced with the possible higher risks of opportunistic infections and lymphoproliferative diseases. The possible effect of combination therapy in IBD also on vaccine response needs to be better investigated.

The aims of our study were first to evaluate the immune response to the pH1N1 vaccine in patients with IBD treated with anti-TNF-α alone or combined with immunosuppressive therapy, and to compare them with healthy control subjects; then to analyze the safety of influenza A/H1N1 vaccine in IBD patients and lastly to determine the effects of pH1N1 vaccine on IBD clinical activity.

Methods

Subjects

This prospective observational study was conducted at the outpatients IBD clinic of the Catholic University Sacro Cuore in Rome, Italy, from November 2009 to January 2010. The protocol was approved by our hospital's ethics committee, and written informed consent was obtained from all participants before enrollment. We enrolled 62 consecutive IBD patients on maintenance treatment at our IBD outpatient clinic with anti TNF-α agents (Infliximab, Adalimumab, Certolizumab pegol) for at least 4 months (median 16, range 4–78). Mean age of patients was 40 years (range 18–75), while mean age of HC was 28 (range 26–55). 26 patients were affected by Ulcerative Colitis (UC) and 36 by Crohn's disease (CD). Patients were divided into two subgroups: those on anti TNF-α monotherapy (N = 47) and those on anti TNF-α combined with immunosuppressants (IS) or corticosteroids (N = 15). Combined therapy was as follows: azathioprine/6MP (2–2,5 mg/kg) in ten patients, methotrexate (10–15 mg/week) in four patients and methyl-prednisolone (20 mg/day) in one patient. All IS were at stable dose from at least 4 months, while patients on monotherapy were off IS therapy from at least 4 months. We also enrolled 31 healthy controls (HC) among hospital personnel, during the pandemic vaccine campaign, on a voluntary basis. All patients and controls lived in the same geographic area (central Italy).

Study protocol

At baseline (T0), a physical examination was performed on all patients, and blood specimens were obtained to measure clinical and laboratory parameters of IBD activity. We assayed erythrocyte sedimentation rate (ESR), C reactive protein (CRP), lymphocyte count and percentage and then we stored serum samples at − 80 °C for later assay of IgG antibodies to A/California/7/2009 (H1N1) by hemagglutination inhibition (HAI). Disease location and behavior were described according to the Montreal classification,23 and data were collected from patients' charts and interviews, relative to the duration of disease and to the duration of anti TNF-α therapy. We evaluated the disease activity in patients with ulcerative colitis (UC) by partial Mayo score (pMayo),24 while in patients with Crohn's disease by Harvey Bradshaw index (HBI).25 All the patients and controls were vaccinated with the MF59-adjuvanted vaccine A/California/7/2009 (H1N1), Focetria®, Novartis, the only p2009 influenza vaccine available in Italy. Each 0.5 ml dose of vaccine has the following composition: hemagglutinin (HA) and neuraminidase (NA) antigens from the influenza virus strain recommended by WHO/EU for the pandemic ≥ 7.5 μg HA (propagated in eggs) — employed strain NYMC X-181; adjuvant MF59C.1 composed of: squalene 9.75 mg, polysorbate 80 1.175 mg, sorbitan trioleate 1.175 mg; other ingredients: sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride hexahydrate, calcium chloride dehydrate, Thiomersal (included only in multi-dose vials), sodium citrate, citric acid, and water for injections.26

The subjects were contacted by phone at 72 h after immunization to document the occurrence of adverse events.

At T1, 4–6 weeks after the vaccination, a physical examination was performed on all patients, HBI or pMayo was calculated, as appropriate, and blood specimens were obtained to measure ESR, CRP, lymphocyte count and percentage and to obtain serum samples to store at − 80 °C for later assay by HAI. Data were recorded also concerning the occurrence of previous flu vaccination in the last 3 years (2006, 2007, 2008), and the concomitant 2009 seasonal flu vaccination.

Blood samples were obtained at T0 and T1 also from HC and stored in the same conditions.

Outcomes

The primary outcome of the study was the immune response to H1N1 vaccine in HC and patients with IBD as measured by pre immunization and post immunization hemagglutination inhibition (HAI) titer. The secondary outcome was the safety of the H1N1 vaccine. The tertiary outcome was the effect of H1N1 vaccine on IBD clinical activity.

Hemagglutination inhibition (HAI) assay

HAI was performed simultaneously on all study samples according to previously described method.27 Briefly, the sera were pretreated with receptor destroying enzyme (RDE II, Seiken Co Ltd) for 20 h at 37 °C then heated at 56 °C for 60 min, 25 μl of serial dilutions of sera was incubated with 4 HA units of whole vaccine for 1 h at RT and 50 μl of 1.25% suspension of human RBC type O was added and after 2 h at RT titers were determined. HAI results were reported as follows: seroprotection rate (% subjects with T1 titer ≥ 1:40), seroconvertion rate (% subjects having ≥ 4 fold increase in titer), Geometric mean titer (GMT) = antilog (∑ log reciprocal HAI titer) / number of subjects and the Factor increase of GMT between T1 and T0, as described.28

We considered as the cut off level for each measure of immunogenicity those indicated for adults by the European Committee for Proprietary Medicinal Products (CPMP) for the assessment of influenza vaccines, i.e. 70% seroprotection, 40% seroconversion and > 2.5 factor increase of GMT.29 In particular, for a virus with the potential to cause pandemics, all three criteria should be fulfilled.30

Statistical analysis

We calculated the sample size based on the study of Mamula et al.,16 who detected for H1N1 vaccine a difference in response ranging from 34 to 12% between IBD patients on anti TNF-α and/or IS therapy and HC. With α value of 0.05 and a power of 80% the minimal required sample to detect a difference of 25% was 29. We enrolled a higher number of patients to allow subgroup comparison. Data analysis was undertaken with the use of MedCalc® software, version 9.2.1.0. We used a two-side Fisher's exact test to compare proportions between vaccine groups. All p values reported are two-sided, with no adjustment for multiple testing; values of 0.05 or less were considered to indicate statistical significance. For immunogenicity analyses, the geometric mean antibody titers at each time point were used. Geometric mean titers and 95% confidence intervals were computed by taking the exponent (log10) of the mean and of the lower and upper limits of the 95% confidence intervals of the log10 transformed titers. Normality was checked by D'Agostino-Pearson test. The group comparisons were performed by Mann Whitney test, Wilcoxon test and t test for paired and unpaired samples (two-tailed) and statistical correlations were tested by Spearman's rho and regression analysis, as appropriate.

Results

The demographic and clinical characteristics of IBD patients are shown in Tables 1, 2 and 3.

The HAI response of patients and controls to the A/H1N1 influenza vaccination is shown in Table 4. Pre-vaccination HAI titer ≥ 1:40 was comparable between IBD patients and controls (54% vs 64%, p = not significant by χ2test). IBD patients on anti TNF-α therapy showed rates of seroprotection at T1 comparable to those of HC. The seroconversion rate (≥ 4 fold increase in titer at T1) was lower than HC in the whole population of patients (p = 0.009) and in the group on anti TNF-α therapy, either alone (p = 0.034) or combined with IS (p = 0.011). The GMT at T1 was significantly lower in patients on anti TNF-α combined with IS compared both with HC and with patients on monotherapy (p = 0.011 and p = 0.017, respectively). The reverse cumulative distribution curves of HAI titers at T1 are shown in Fig. 1, showing the markedly reduced titers of patients on anti TNF-α combined with IS. The factor increase of GMT at T1 was significantly lower in the IBD patients on anti TNF-α therapy versus the HC (p = 0.042), and was lower in the group of patients on combined therapy versus those on anti TNF-α monotherapy (p = 0.0048) and versus the HC (p = 0.0015). In the patients on combined therapy the seroconversion rate and the factor increase of GMT did not reach the EMEA requirements30 for vaccine immunogenicity in a pandemic setting, but those on TNF-α monotherapy did (Table 4).

No correlation was found between seroconversion rate, GMT and factor increase with age, gender, duration of disease and treatment, with the type of anti TNF-α, disease activity, Montreal classification, and flu vaccination in the last 3 years. The GMT at T1 of the IBD patients was significantly correlated with previous or concomitant vaccination for 2009 seasonal influenza (p = 0.036) and with GMT at T0 (p = 0.027). Multiple regression analysis of GMT at T1 revealed the following independent variables: combined therapy (p = 0.036) and the previous vaccination for 2009 seasonal influenza (p = 0.017). After exclusion of the subjects vaccinated for seasonal flu the GMT at T1 was 94 for patients on anti TNF-α monotherapy and 53 for those on combined therapy (p = 0.054) and the factor increase was 4.5 vs. 1.9, respectively (p = 0.0068).

As far as the safety was concerned, none of the studied patients complained of injection site symptoms after the vaccination; 2 patients presented headache, one of them on combined therapy, 2 patients presented malaise and 1 patient presented shivering. None of them reported a flare of the IBD at the T1 visit. No difference was found among the mean HBI and p Mayo scores at T1 versus T0 (Table 5).

Discussion

Our study has shown that our population of IBD patients on anti TNF-α therapy has reached the minimum seroprotective titer of 1:40 at HAI in proportions comparable to HC during the pandemic 2009 A/H1N1 vaccine campaign. However when the response is analyzed in a quantitative way significant differences are detectable: the percentage of patients achieving seroconversion is lower than HC and, furthermore, seroconversion rate is lower than HC in the patients on anti TNF-α therapy combined with immunosuppressors. In these patients on combined therapy, in particular, the GMT after the vaccination is significantly lower than in patients on anti TNF-α monotherapy. A limitation of our study is the limited number of enrolled patients and the lack of an IBD control group without IS.

In general, vaccine studies in IBD are very difficult to compare. Authors have collected patients affected by different IBD pathologies, at different stages of clinical activity. The effect of age, which is well known to affect immune response to vaccination,27 has not been always taken in account. Also the effect of immunosuppressive treatments is often difficult to interpret: some studies compared anti TNF-α to other IS or to combined IS therapy, or to non IS drugs, like mesalamine. Furthermore, not all studies have included HC and they have not employed the same measures of the immune response to influenza vaccines. A diversity in immunization status before vaccination could happen in different years and in distinct populations and different vaccination schedules were employed in some studies.

The first studies on influenza vaccine in IBD were conducted in pediatric populations vaccinated with trivalent inactivated vaccine (TIV). In these studies16 it was shown that children with IBD had a lower seroconversion rate compared to HC and that patients receiving both infliximab and immunomolulators were seroconverting less than HC. Another study on pediatric IBD patients receiving 2 doses of TIV, one month apart,17 showed a high prevalence of seroconversion in IBD patients regardless of treatment. The very few studies conducted in adult IBD patients confirmed that the immune response to vaccinations in IBD patients may depend on the type of immunosuppressive therapy they receive, together with anti TNF-α therapy. Gelinck19 studied 112 autoimmune patients treated with TNF-α inhibitors and showed that the percentage of subjects who had a seroprotective titer was high, but post-vaccination titers were significantly lower in subjects treated with TNF-α inhibitors as compared to HC. The A/H1N1 pandemic vaccine campaign represented a good chance to explore the response to a monovalent vaccine for a “relatively” new virus. Two recent studies were conducted during the 2009 pandemic vaccine campaign. Molnar et al.20 studied 24 adult IBD patients (15 on IS, 7 on biologicals and 2 on combined therapy) by a different method (microneutralization assay). The authors showed seroprotective titers in every patient independently from the type of medication. The study, although limited by small number and lack of pre-vaccination measures, indicated, similarly to our study, that vaccination is able to induce seroprotection in the majority of IBD patients. At variance, a recently published study18 described the results of a prospective study on 105 adult IBD patients who received a single dose of non adjuvanted A/H1N1 2009 pandemic vaccine. 28 patients were non immunosuppressed and 77 immunosuppressed. This study has shown a low rate of seroprotection, particularly among patients on IS. However, no HC were included and the overall proportion of seroprotection was 50%, with no differences among immunosuppressed and non immunosuppressed patients. In this population, at variance with ours, the pre-vaccination seroprotection rate was low.

The immune response to vaccines in IBD can be discussed in the frame of vaccine response in other immune mediated inflammatory diseases (IMID).31 Several studies have shown that adult patients with rheumatoid arthritis (RA), treated with anti-TNFα, have similar antibody titer levels to influenza vaccine compared to controls.32,33 Other studies in patients treated with IS or anti TNF-α have indicated some reduction in the response, however a protective immune response after influenza vaccination was achieved in the majority of patients.3436 The only randomized controlled trial (RCT) available in this field37 was conducted in RA patients who were treated with adalimumab or placebo and underwent influenza and pneumococcal vaccination, showing no effect of biological therapy on vaccination.

The safety of vaccines has been a concern both for IBD patients and their treating physicians, and this may be one of the reasons for the poor compliance to influenza vaccination that has been reported in these patients.38 The possibility that immune mediated diseases could flare after a vaccination cannot theoretically be excluded and, indeed, a case report has been published.39 However a recent observational study40 was conducted on 575 IBD patients during the pandemic vaccine campaign, to evaluate the safety of both adjuvanted and not adjuvanted vaccines, containing different virus antigen doses. The authors observed at four weeks after the vaccination no reactivation of the disease in the large majority of patients (96.7% CD and 95.6% UC), and they found that the increase of disease activity was not related to the type of vaccine. Our study confirmed those findings and also showed the lack of change of laboratory indices of inflammatory activity such as CRP and ESR, as well as of lymphocyte count and percentages.

Our study has shown a suboptimal response to A/H1N1 2009 vaccine in IBD patients on combined therapy with anti TNF-α and IS, although the seroprotective 1:40 titer was reached by the majority of patients. Similar results to ours where there was a normal response among non immunosuppressed IBD patients and an impaired response in IBD patients on combined immunosuppression were also described for pneumococcal polysaccharide vaccination.41

The real meaning of these findings in terms of reduced protection from infection is unknown, however, considering the EMEA requirements for influenza vaccine in a pandemic setting, the response of IBD patients on combined therapy can be considered at risk to be insufficient. So our results clearly indicate quantitatively reduced response to influenza vaccine in IBD patients on combined immunosuppression. Different strategies to further overcome this reduced response can be explored. In at-risk groups, post-vaccination testing could be proposed. A double injection schedule with a recall one month after the first injection could also be used. Given our results the use of adjuvanted vaccine in IBD patients could be explored. The efficacy and safety of these vaccine strategies in IBD patients on immunosuppressive therapy need to be ascertained by appropriately designed double blind randomized controlled studies, addressing different patient categories and including control groups.

Funding

This research received no specific funding.

Competing interests

There are no competing interests.

Contributorship

LG, GA, DF, BBB: conception and design, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content and final approval of the version to be published; MR, MM, CF, DP, GM: data collection; AA, AP, IDV, GLR: analysis and interpretation of data revising the article for important intellectual content and final approval of the version to be published.

References

1
Hugot
J.P.
Chamaillard
M.
Zouali
H.
Lesage
S.
Cézard
J.P.
Belaiche
J.
et al
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Nature
 
411
2001
599
603
2
Ogura
Y.
Bonen
D.K.
Inohara
N.
Nicolae
D.L.
Chen
F.F.
Ramos
R.
Britton
H.
Moran
T.
Karaliuskas
R.
Duerr
R.H.
Achkar
J.P.
Brant
S.R.
Bayless
T.M.
Kirschner
B.S.
Hanauer
S.B.
Nuñez
G.
Cho
J.H.
A frameshift mutation in NOD2 assoiated with susceptibily to Crohn's disease
Nature
 
411
2001
603
606
3
Baldassano
R.N.
Bradfield
J.P.
Monos
D.S.
Kim
C.E.
Glessner
J.T.
Casalunovo
T.
et al
Association of variants of the interleuckin-23 receptor gene with susceptibility to pediatric Crohn's disease
Clin Gastroenterol Hepatol
 
5
2007
972
976
4
Duerr
R.H.
Taylor
K.D.
Brant
S.R.
Rioux
J.D.
Silverberg
M.S.
Daly
M.J.
et al
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Science
 
314
2006
1461
1463
5
Rau
R.
Fitzhugh
C.D.
Baird
K.
Cortez
K.J.
Li
L.
Fischer
S.H.
et al
Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy
Pediatr Infect Dis J
 
27
2008
265
268
6
Deutsh
D.E.
Olson
A.D.
Kraker
S.
Dickinson
C.J.
Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine
J Pediatr Gastroenterol Nutr
 
20
1995
351
353
7
Korelitz
B.I.
Fuller
S.R.
Warman
J.I.
Goldberg
M.D.
Shingles during the course of treatment with 6 mercaptopurine for inflammatory bowel disease
Am J Gastroenterol
 
94
1999
424
426
8
Keane
J.
Gershon
S.
Wise
R.P.
Mirabile-Levens
E.
Kasznica
J.
Schwieterman
W.D.
et al
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
N Engl J Med
 
345
2001
1098
1104
9
Fraser
C.
Donnelly
C.A.
Cauchemez
S.
Van Kerkhove
M.D.
Hollingsworth
T.D.
Griffin
J.
et al
Pandemic potential of a strain of influenza A (H1N1) virus in humans
Science
 
324
5934
Jun 19 2009
1557
1561
[Epub 2009 May 11]
10
Dowood
F.S.
Jaiun
S.
Finelli
L.
Shaw
M.W.
Lindstrom
S.
Garten
R.J.
et al
Emergence of a novel swine origin influenza A (H1N1) virus in humans
N Engl J Med
 
360
25
2009
2605
2615
11
Thompson
W.W.
Shay
D.K.
Weintraub
E.
Brammer
L.
Cox
N.
Anderson
L.J.
et al
Mortality associated with influenza and respiratory syncytial virus in the United States
JAMA
 
289
2
2003
179
186
12
Kelly
H.
Grant
K.
Williams
S.
Smith
D.
H1N1 swine origin influenza infection in the United States and Europe in 2009 may be similar to H1N1 seasonal influenza infection in two Australian states in 2007 and 2008
Influenza Other Respi Viruses
 
3
4
2009
183
188
13
Sands
B.E.
Cuffari
C.
Katz
J.
Kugathasan
S.
Onken
J.
Vitek
C.
et al
Guidelines for immunizations in patients with inflammatory bowel disease
Inflamm Bowel Dis
 
10
5
2004 Sep
677
692
14
Rahier
J.F.
Ben-Horin
S.
Chowers
Y.
Conlon
C.
De Munter
P.
D'Haens
G.
et al
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J Crohns Colitis
 
3
2
Jun 2009
47
91
15
Rahier
J.F.
Yazdanpanah
Y.
Viget
N.
Viget
N.
Travis
S.
Colombel
J.F.
Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease
Aliment Pharmacol Ther
 
31
1
Jan 2010
5
10
16
Mamula
P.
Markowitz
J.E.
Piccoli
D.A.
Klimov
A.
Cohen
L.
Baldassano
R.N.
Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease
Clin Gastroenterol Hepatol
 
5
2007
851
856
17
Lu
Y.
Jacobson
D.L.
Ashworth
L.A.
Grand
R.J.
Meyer
A.L.
McNeal
M.M.
et al
Immune response to influenza vaccine in children with inflammatory bowel disease
Am J Gastroenterol
 
104
2
Feb 2009
444
453
18
Cullen
G.
Bader
C.
Korzenik
J.R.
Sands
B.E.
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease
Gut
 
61
3
Mar 2012
385
391
Epub 2011 Jul 13
19
Gelinck
L.B.
van der Bijl
A.E.
Beyer
W.E.
Visser
L.G.
Huizinga
T.W.
van Hogezand
R.A.
et al
The effect of anti-tumor necrosis factor alpha treatment on the antibody response top influenza vaccination
Ann Rheum Dis
 
67
2008
713
716
20
Molnár
T.
Farkas
K.
Jankovics
I.
Melles
M.
Nagy
F.
Szepes
Z.
et al
Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy
Am J Gastroenterol
 
106
2
2011 Feb
370
372
21
Colombel
J.F.
Sandborn
W.J.
Reinisch
W.
Mantzaris
G.J.
Kornbluth
A.
Rachmilewitz
D.
et al
Infliximab, azathioprine, or combination therapy for Crohn's disease
N Engl J Med
 
362
15
Apr 15 2010
1383
1395
22
Panaccione
R.
Ghosh
S.
Middleton
S.
Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial
J Crohns Colitis
 
5
1
Feb 2011
S8
23
Satsangi
J.
Silverberg
M.S.
Vermeire
S.
Colombel
JFl.
The Montreal classification of IBD: controversies, consensus, and implications
Gut
 
55
2006
749
753
24
Lewis
J.D.
Chuai
S.
Nessel
L.
Lichtenstein
G.R.
Aberra
F.N.
Ellenberg
J.H.
Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
Inflamm Bowel Dis
 
14
12
Dec 2008
1660
1666
25
Harvey
R.F.
Bradshaw
J.M.
A simple index of Crohn's disease activity
Lancet
 
1
1980
514
26
Focetria® prescribing information
 
2009
Novartis Vaccines & Diagnostics
Novartis Vaccines & Diagnostics
27
Frasca
D.
Diaz
A.
Romero
M.
Phillips
M.
Mendez
N.V.
Landin
A.M.
et al
Unique biomarkers for B cell function predict the serum response to pandemic H1N1 influenza vaccine
Int Immunol
 
24
3
Mar 2012
175
182
[Epub 2012 Jan 25]
28
McElhaney
J.E.
Meneilly
G.S.
Lechelt
K.E.
Beattie
B.L.
Bleackley
R.C.
Antibody response to wholevirus and split-virus influenza vaccines in successful ageing
Vaccine
 
11
10
1993
1055
1060
29
EMEA Committee for Human Medicinal products Note for Guidance on Harmonization Of Requirements for Influenza Vaccines, CPMP/BWP/214/96.
30
EMEA Committee for Human Medicinal products Guideline on Influenza Vaccines prepared from Viruses with the Potential to cause a Pandemic and intended for Use outside of the Core Dossier Context EMEA/CHMP/VWP/263499/2006.
31
Rahier
J.F.
Moutschen
M.
Van Gompel
A.
Van Ranst
M.
Louis
E.
Segaert
S.
et al
Vaccinations in patients with immune-mediated inflammatory diseases
Rheumatology (Oxford)
 
49
10
Oct 2010
1815
1827
32
Chalmes
A.
Scheifele
D.
Ptterson
C.
Williams
D.
Weber
J.
Shuckett
R.
et al
Immunization of patients with rheumatoid arthritis against influenza : a study of vaccine safety and immunogenicity
J Rheumatol
 
21
1994
1203
1206
33
Kubota
T.
Nii
T.
Nanki
T.
Kohsaka
H.
Harigai
M.
Komano
Y.
et al
Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis
Mod Rheumatol
 
17
2007
531
533
34
Fomin
I.
Caspi
D.
Levy
V.
Varsano
N.
Shalev
Y.
Paran
D.
et al
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers
Ann Rheum Dis
 
65
2
Feb 2006
191
194
[Epub 2005 Jul 13]
35
Kapetanovic
M.C.
Saxne
T.
Nilsson
J.A.
Geborek
P.
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients
Rheumatology (Oxford)
 
46
4
Apr 2007
608
611
[Epub 2006 Nov 18]
36
Aikawa
N.E.
Campos
L.M.
Silva
C.A.
Carvalho
J.F.
Saad
C.G.
Trudes
G.
et al
Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease
J Rheumatol
 
39
1
2012 Jan
167
173
[Epub 2011 Nov 15]
37
Kaine
J.L.
Kivitz
A.J.
Birbara
C.
Luo
A.Y.
Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab
J Rheumatol
 
34
2
Feb 2007
272
279
38
German IBD Study Group
Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis
Dtsch Med Wochenschr
 
136
18
May 2011
939
943
39
Lisotti
A.
Roda
G.
Brillanti
S.
Roda
E.
Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations
Dig Liver Dis
 
42
12
Dec 2010
909
910
[Epub 2010 Apr 24]
40
Rahier
J.F.
Papay
P.
Salleron
J.
Sebastian
S.
Marzo
M.
Peyrin-Biroulet
L.
et al
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
Gut
 
60
4
Apr 2011
456
462
[Epub 2011 Jan 26]
41
Melmed
G.Y.
Agarwal
N.
Frenck
R.W.
Ippoliti
A.F.
Ibanez
P.
Papadakis
K.A.
et al
Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease
Am J Gastroenterol
 
105
1
Jan 2010
148
154
[Epub 2009 Sep 15]
Figure 1

Response to influenza A/H1N1 vaccine in patients with IBD on anti TNF-α. Reverse cumulative distribution curves of HI titers at T1 of patients and HC.

Figure 1

Response to influenza A/H1N1 vaccine in patients with IBD on anti TNF-α. Reverse cumulative distribution curves of HI titers at T1 of patients and HC.

Table 1

Demographic and clinical characteristic of the studied subjects.

 Age⁎ Gender (M/F) Disease duration (years)⁎ Previous flu vaccination 2006–2008 n (%) Concomitant 2009 seasonal flu vaccination n (%) 
All IBD 62 40 (18–75) 28/34 7.5 (1–32) 23 (37) 20 (32) 
Crohn's disease 36 38 (18–69) 22/14 7.5 (1–32) 12 (33) 13 (36) 
Ulcerative colitis 26 44 (29–75) 6/20 7.5 (2–21) 11 (42) 7 (27) 
Anti TNF monotherapy 47 40 (18–69) 24/23 8 (1–32) 17 (36) 17 (36) 
Anti TNF and IS 15 47 (20–75) 11/4 7 (1–21) 6 (40) 3 (20) 
HC 31 31.5 (20–55) 10/21  na 9 (29) 
 Age⁎ Gender (M/F) Disease duration (years)⁎ Previous flu vaccination 2006–2008 n (%) Concomitant 2009 seasonal flu vaccination n (%) 
All IBD 62 40 (18–75) 28/34 7.5 (1–32) 23 (37) 20 (32) 
Crohn's disease 36 38 (18–69) 22/14 7.5 (1–32) 12 (33) 13 (36) 
Ulcerative colitis 26 44 (29–75) 6/20 7.5 (2–21) 11 (42) 7 (27) 
Anti TNF monotherapy 47 40 (18–69) 24/23 8 (1–32) 17 (36) 17 (36) 
Anti TNF and IS 15 47 (20–75) 11/4 7 (1–21) 6 (40) 3 (20) 
HC 31 31.5 (20–55) 10/21  na 9 (29) 

Median (range).

Table 2

Montreal classification.

 A1 A2 A3 L1 L2 L3 B1 B2 B3 E2 E3 
Crohn's disease 22 13 19 14 10 12   
Ulcerative colitis           10 16 
 A1 A2 A3 L1 L2 L3 B1 B2 B3 E2 E3 
Crohn's disease 22 13 19 14 10 12   
Ulcerative colitis           10 16 
Table 3

Type of anti TNF-α treatment of the IBD patients (number of patients).

 Crohn's disease Ulcerative colitis Total 
Anti TNF monotherapy 27 20 47 
Infliximab 14 19 33 
Adalimumab 12 13 
Certolizumab pegol 
Anti TNF and IS 15 
Infliximab 
Adalimumab 
 Crohn's disease Ulcerative colitis Total 
Anti TNF monotherapy 27 20 47 
Infliximab 14 19 33 
Adalimumab 12 13 
Certolizumab pegol 
Anti TNF and IS 15 
Infliximab 
Adalimumab 
Table 4

Response to the influenza A/H1N1 vaccination in IBD patients on anti TNF-α therapy.

 IBD on anti TNF-α Anti TNF-α monotherapy Anti TNF-α + IS HC EMEA requirements* 
Seroprotection n/total (%) 55/62 (88) 43/47 (91) 12/15 (80) 25/31 (81) 70% 
Seroconversion n/total (%) 28/62 (45)∆ 23/47 (49)∞ 5/15 (33)& 23/31 (74) 40% 
GMT at T0 (95% CI) 34.58 (30.43–39.31) 35 (30.12–40.73) 33.25 (25.38–43.56) 29.25 (25.71–33.26)  
GMT at T1 (95% CI) 102.30 (77.76–134.60) 122.7 (88.43–170.23) 57.9 (38.54–87)‡@ 139.91 (90.8–215.63)  
Factor increase of GMT (95% CI) 2.96 (2.25–3.87)¤ 3.5 (2.52–4.86) 1.74 (1.21–2.5)§◆ 4.68 (3.25–7.05) 2.5 
 IBD on anti TNF-α Anti TNF-α monotherapy Anti TNF-α + IS HC EMEA requirements* 
Seroprotection n/total (%) 55/62 (88) 43/47 (91) 12/15 (80) 25/31 (81) 70% 
Seroconversion n/total (%) 28/62 (45)∆ 23/47 (49)∞ 5/15 (33)& 23/31 (74) 40% 
GMT at T0 (95% CI) 34.58 (30.43–39.31) 35 (30.12–40.73) 33.25 (25.38–43.56) 29.25 (25.71–33.26)  
GMT at T1 (95% CI) 102.30 (77.76–134.60) 122.7 (88.43–170.23) 57.9 (38.54–87)‡@ 139.91 (90.8–215.63)  
Factor increase of GMT (95% CI) 2.96 (2.25–3.87)¤ 3.5 (2.52–4.86) 1.74 (1.21–2.5)§◆ 4.68 (3.25–7.05) 2.5 

Fisher's test: IS immunosuppressant - HC healthy controls - GMT geometric mean titer

p = 0.009 vs HC

p = 0.034 vs HC

&

p = 0.011 vs HC

t test:

p = 0.011 vs HC

¤

p = 0.042 vs HC

§

p = 0.0015 vs HC

@

p = 0.017 vs anti TNF mono

p = 0.0048 vs anti TNF mono

Table 5

Activity scores and laboratory parameters of IBD patients before and after A/H1N1 influenza vaccination mean values (95% CI).

 n. T0 T1 p values (paired t test) 
Harvey Bradshaw index 36 1.64 (0.73–2.56) 1.86 (0.93–2.79) 0.15 
Partial Mayo score 26 2.61 (1.58–3.65) 3 (2.01–3.98) 0.18 
ESR (mm) 62 19.67 (15.7–23.63) 20.08 (15.88–24.29) 0.73 
CRP (mg/l) 62 5.05 (2.5–7.57) 5.2 (2.25–8.16) 0.83 
Peripheral blood lymphocyte count (cells/μl) 62 2153 (1954–2351) 2083 (1865–2301) 0.42 
Peripheral blood lymphocyte % 62 32.21 (29.66–34.76) 31.19 (28.38–34) 0.37 
 n. T0 T1 p values (paired t test) 
Harvey Bradshaw index 36 1.64 (0.73–2.56) 1.86 (0.93–2.79) 0.15 
Partial Mayo score 26 2.61 (1.58–3.65) 3 (2.01–3.98) 0.18 
ESR (mm) 62 19.67 (15.7–23.63) 20.08 (15.88–24.29) 0.73 
CRP (mg/l) 62 5.05 (2.5–7.57) 5.2 (2.25–8.16) 0.83 
Peripheral blood lymphocyte count (cells/μl) 62 2153 (1954–2351) 2083 (1865–2301) 0.42 
Peripheral blood lymphocyte % 62 32.21 (29.66–34.76) 31.19 (28.38–34) 0.37